Portfolio News
Sofinnova Capital
Enthera Pharmaceuticals, Boston Children’s Hospital and the University of Milan reveal use of novel pathway to restore pancreatic cell function in diabetes
Related Company
Enthera PharmaceuticalsRelated Deal lead
Silvano SpinelliRelated Deal lead
Graziano SeghezziRelated Strategy
CapitalEnthera Pharmaceuticals, a Sofinnova Partners portfolio company, together with scientific partners Boston Children’s Hospital (Harvard Medical School) and the University of Milan, announced on Feb. 3 a study detailing the discovery of a harmful cellular pathway that causes the death of pancreatic beta cells that make insulin.
Enthera aims to develop a therapeutic to block the pathway to treat type 1 diabetes. The study, published Feb. 3 in Nature Communications, used three mouse models of diabetes, and found protective effects when the pathway was blocked genetically or with an antibody. Studies of human cells and diabetes patients were consistent with the mouse findings.
Data from the study reinforced the idea that the ‘IGFBP3/TMEM219’ apoptosis pathway is a key regulator of pancreatic beta cells and a novel therapeutic target for type 1 diabetes.
“The common thought for type 1 diabetes is that it autoimmune,” said Paolo Fiorina, MD, PhD, Enthera's founder. “But immunotherapy doesn’t completely cure diabetes. We think that dysregulation of beta cell homeostasis also plays a role and that IGFBP3 acts as a ‘betatoxin.’”
Enthera, founded in 2016, is developing biologics based on these discoveries. First-in-human tests of an antibody treatment to block the IGFBP3/TMEM219 pathway could begin as early as September 2022 in Europe.
For more information, read:
The article in Nature Communications
Related News
Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia
Enthera Pharmaceuticals Announces Publication in the Journal of Clinical Investigation Supporting the Clinical Development of Ebrasodebart
GlycoEra AG raises $130 million to advance novel pipeline of extracellular protein degraders for the treatment of autoimmune diseases
Biotalys and AgroFresh Partner to protect fresh produce
BrightHeart obtains third FDA clearance and PCCP approval, becoming first to offer one integrated solution for real-time fetal heart documentation and CHD detection